Swiss pharmaceutical giant Novartis has finalised the purchase of a 25 per cent stake of eye care company Alcon for $10.4 billion (SFr10.64 billion) in cash from Nestlé.This content was published on July 8, 2008 - 10:49
The drugmaker said in a statement on Tuesday that the price was $200 million less than previously announced, due to a dividend payment.
The purchase is the first step in Novartis' agreement to acquire a majority stake in American firm Alcon from Swiss food multinational Nestlé. The deal was announced in April.
Novartis has the right to buy - and Nestlé the right to sell – a further 52 per cent stake in Alcon, for a price of not more than $28 billion. The pharmaceutical company is already active in the eye care business with its Ciba Vision unit.
Fort Worth-based Alcon employs 14,500 people in 75 countries. After the Novartis buyout, it will remain an independent company.
This article was automatically imported from our old content management system. If you see any display errors, please let us know: firstname.lastname@example.org